HOWL
HEALTHCAREWerewolf Therapeutics Inc
$0.65-0.02 (-2.91%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving HOWL Today?
No stock-specific AI insight has been generated for HOWL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.53$2.38
$0.65
Fundamentals
Market Cap$32M
P/E Ratio—
EPS$-1.33
Dividend Yield—
Dividend / Share—
ROE-1.2%
Profit Margin—
Debt / Equity—
Trading
Volume304K
Avg Volume (10D)—
Shares Outstanding48.6M
HOWL News
20 articles- Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate UpdatesYahoo Finance·May 7, 2026
- Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate UpdatesGlobeNewswire Inc.·Mar 27, 2026
- Werewolf Therapeutics Announces Plan to Explore Strategic AlternativesYahoo Finance·Feb 24, 2026
- Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE ResultsYahoo Finance·Jan 13, 2026
- Werewolf Therapeutics Announces Pipeline and Business UpdatesYahoo Finance·Dec 18, 2025
- Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Dec 15, 2025
- Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual MeetingYahoo Finance·Nov 7, 2025
- Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Nov 4, 2025
- Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri UptakeYahoo Finance·Oct 31, 2025
- Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View RaisedYahoo Finance·Oct 29, 2025
- BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene TherapyYahoo Finance·Oct 28, 2025
- Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales NilYahoo Finance·Oct 23, 2025
- Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's WhyYahoo Finance·Oct 23, 2025
- Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of CancerYahoo Finance·Oct 8, 2025
- Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual MeetingYahoo Finance·Oct 3, 2025
- 3 Promising Penny Stocks With Market Caps Under $700MYahoo Finance·Sep 25, 2025
- Werewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy?Yahoo Finance·Sep 8, 2025
- Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 2, 2025
- Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Aug 14, 2025
- XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass EstimatesYahoo Finance·Aug 13, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$0.67
Day High$0.00
Day Low$0.00
52 Week High$2.38
52 Week Low$0.53
52-Week Range
$0.53$2.38
$0.65
Fundamentals
Market Cap$32M
P/E Ratio—
EPS$-1.33
Dividend Yield—
Dividend / Share—
ROE-1.2%
Profit Margin—
Debt / Equity—
Trading
Volume304K
Avg Volume (10D)—
Shares Outstanding48.6M
About Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapies designed to boost the body's immune system for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—